MRE for Diagnosis of Pancreatic Masses

Recruiting now

Conditions studied: Pancreatic Neoplasm, Magnetic Resonance Imaging

In brief

Pancreatic ductal adenocarcinoma (PDAC) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic or predictive factors facilitates risk stratification and prospective assessment in clinical trials. The extracellular matrix (ECM) surrounding PDAC often exhibits a large number of interstitial fibrosis, which is closely related to the formation, development and metastasis of PDAC. High order three-dimensional MR elastography (3D-MRE) allows non-invasive measurements of sheer stiffness in normal pancreas and pancreatic lesions. However, there are no reports about the application of MRE imaging biomarkers to predict the prognosis of PDAC at home and abroad.

Key facts

Study ID: NCT06526442
Run by: Yu Shi
People needed: 200
Starts: 2020-10-09
Expected to finish: 2027-06-01
Last updated by the study team: 2026-02-13

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

granting of written informed consent
age ≥18 years
no history of extrapancreatic malignancy
no preoperative biliary drainage
definitive histologic evidence of PDAC in excisional biopsy
with no less than three months of postoperative mortality or six months of follow- up

You may not qualify if…

inability to re-review of tissue specimens
unacceptable estimates of MRE parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and MRE hardware disconnection
tumor diameters <1.0 cm
withdrawal/dropout during follow-up

Where it is running

Shengjing hospital of china medical university — Shenyang, Liaoning, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.